ESR1 and breast cancer: Different breast cancer subtypes (Luminal A, Luminal B, Her2+, and TNBC) show unique immune cell types with distinct gene expressions, suggesting dynamic immune interactions with ER, PR and Her2 status between subtypes 5, which can further indicates differential prognosis6.